Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) was upgraded by investment analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a report released on Friday.

Other research analysts have also recently issued research reports about the stock. Jefferies Group LLC decreased their price target on shares of Bellicum Pharmaceuticals from $19.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, May 9th. Cantor Fitzgerald set a $32.00 price target on shares of Bellicum Pharmaceuticals and gave the stock a “buy” rating in a report on Saturday, June 24th. Ladenburg Thalmann Financial Services set a $31.00 price target on shares of Bellicum Pharmaceuticals and gave the stock a “buy” rating in a report on Saturday, June 24th. Raymond James Financial, Inc. set a $18.00 price target on shares of Bellicum Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, August 9th. Finally, Wells Fargo & Company reaffirmed an “outperform” rating and issued a $31.00 price target on shares of Bellicum Pharmaceuticals in a report on Tuesday, June 27th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $26.20.

Shares of Bellicum Pharmaceuticals (NASDAQ BLCM) opened at 8.28 on Friday. The firm’s 50-day moving average price is $10.13 and its 200-day moving average price is $11.97. Bellicum Pharmaceuticals has a one year low of $7.41 and a one year high of $23.11. The company’s market capitalization is $275.11 million.

Bellicum Pharmaceuticals (NASDAQ:BLCM) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.65) by $0.09. Bellicum Pharmaceuticals had a negative return on equity of 70.74% and a negative net margin of 17,957.31%. During the same quarter in the previous year, the firm posted ($0.61) earnings per share. Analysts anticipate that Bellicum Pharmaceuticals will post ($3.02) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Bellicum Pharmaceuticals, Inc. (BLCM) Rating Increased to Sell at BidaskClub” was originally reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this piece on another website, it was illegally copied and republished in violation of international copyright & trademark laws. The original version of this piece can be accessed at https://theolympiareport.com/2017/08/27/bellicum-pharmaceuticals-inc-blcm-rating-increased-to-sell-at-bidaskclub.html.

In other news, VP Ken Moseley sold 13,823 shares of the stock in a transaction on Thursday, July 13th. The shares were sold at an average price of $12.26, for a total value of $169,469.98. Following the sale, the vice president now owns 14,314 shares in the company, valued at $175,489.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider David M. Spencer sold 10,000 shares of the stock in a transaction on Monday, July 10th. The stock was sold at an average price of $11.54, for a total transaction of $115,400.00. The disclosure for this sale can be found here. Insiders sold 24,260 shares of company stock worth $290,048 in the last quarter. Company insiders own 23.30% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the company. State Street Corp raised its stake in Bellicum Pharmaceuticals by 4.9% in the fourth quarter. State Street Corp now owns 326,037 shares of the biopharmaceutical company’s stock worth $4,442,000 after buying an additional 15,142 shares during the last quarter. Teachers Advisors LLC raised its stake in Bellicum Pharmaceuticals by 5.5% in the fourth quarter. Teachers Advisors LLC now owns 35,608 shares of the biopharmaceutical company’s stock worth $485,000 after buying an additional 1,844 shares during the last quarter. Fox Run Management L.L.C. acquired a new stake in Bellicum Pharmaceuticals during the first quarter worth $171,000. Wells Fargo & Company MN raised its stake in Bellicum Pharmaceuticals by 91.0% in the first quarter. Wells Fargo & Company MN now owns 76,081 shares of the biopharmaceutical company’s stock worth $939,000 after buying an additional 36,242 shares during the last quarter. Finally, Eagle Ridge Investment Management acquired a new stake in Bellicum Pharmaceuticals during the first quarter worth $144,000. Hedge funds and other institutional investors own 63.97% of the company’s stock.

About Bellicum Pharmaceuticals

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

Analyst Recommendations for Bellicum Pharmaceuticals (NASDAQ:BLCM)

Receive News & Ratings for Bellicum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.